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Abstract
Upper extremity deep vein thrombosis (UEDVT) may be the first manifestation of venous thoracic outlet syn-
drome (VTOS). It primarily affects young, physically active people. The clinical findings depend on the degree 
of obstruction of the subclavian vein. Correct diagnosis — aided by various imaging modalities — as well as 
rapid initiation of local thrombolytic therapy, surgical decompression of the thoracic outlet (when indications 
are present), and the immediate initiation of anticoagulation therapy aim at successfully restoring the patient’s 
quality of life.
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Introduction
It is estimated that venous thromboembolic diseases 
occur in approximately 200-300 people per 100 000 
persons annually. One-third of these patients presents 
with a pulmonary embolism (PE), while two-thirds 
present with deep vein thrombosis (DVT). Upper 
extremity deep vein thrombosis (UEDVT) accounts 
for approximately 4–10% of all cases of DVT [1, 2]. 
Depending on the etiology, upper extremity DVT can 
be classified as either primary or secondary [3–6].
Primary UEDVT includes spontaneous thrombo-
embolic events “without clear cause,” that may involve 
an underlying latent thrombophilia, or the not yet fully 
understood phenomenon of effort thrombosis, also 
known as Paget-Schroetter syndrome [7].
Secondary UEDVT refers to thrombosis in the set-
ting of endothelial trauma caused by indwelling devices 
(most commonly central venous catheters, pacemaker 
electrodes and leads) and malignancy [3].
The relationship between upper extremity deep 
vein thrombosis and physical effort (effort thrombosis) 
was first observed in 1875 by Paget and then by Von 
Schroetter inspiring them to search for the cause of this 
complication. Currently it is believed that subclavian 
vein thrombosis develops as a consequence of repet-
itive microtrauma due to the compression present in 
thoracic outlet syndrome (TOS) [1, 8]. This term was 
first introduced by Peet in 1956 [9]. It encompasses 
the constellation of clinical findings that may arise as 
a consequence of compression of the neurovascular 
structures passing through the narrow, limited cos-
toclavicular space from the chest towards the upper 
extremity [9, 10]. The subclavian vein, a continuation 
of the axillary vein, and as one of these structures, 
traverses the costoclavicular space with the subclavius 
muscle. It runs anteriorly to the anterior scalene muscle, 
enters the supraclavicular space, where posteriorly 
to the manubrium it joins the internal jugular vein. 
This space is limited anteriorly, from the manubrium, 
by the costoclavicular ligament. Extreme positioning 
of the limb or physical effort changes the anatomical 
conditions, which causes venous microtrauma with 
endothelial damage and precipitates thrombosis [11]. 
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It may lead to a venous compression syndrome which 
some authors refer to as “nutcracker syndrome” [12]. 
This explains the occurrence of acute DVT in young, 
physically active people without a clear cause. 
Primary upper extremity deep vein thrombosis 
may be associated with physical effort in as high as 
20–30% of cases and is a type of venous thoracic outlet 
syndrome (VTOS) [1]. Many researchers consider this 
percentage to be overstated, however, in view of the 
complex pathophysiology and the favorable long-term 
outcomes of proper treatment, VTOS is still a current 
topic of discussion [13]. 
Clinical diagnosis of subclavian vein thrombosis due 
to compression may prove difficult, especially when the 
thrombus involves only a short segment of the vessel. 
In this case, the clinical manifestations are non-specific, 
which yields an error rate of approx. 50% and results 
in erroneous or delayed treatment [10]. The classical 
symptoms of early (10–14 days) upper extremity deep 
vein thrombosis are a consequence of venous conges-
tion. Swelling of the upper limb is the dominating symp-
tom, along with changes in skin color, pain during active 
movements or when pressure is applied to the muscles. 
Late symptoms include the dilation of collateral veins 
in the arm and upper part of the chest. The patient’s 
medical history from the period preceding the onset of 
thrombosis is underestimated. Often, patients report 
discomfort while performing everyday housework in-
volving lifting of the upper limbs. However, provocative 
tests for signs of compression and assessments of blood 
flow are unreliable. Though a positive test result may 
suggest venous compression, objective imaging stud-
ies indicate that 40% of the healthy population has a 
positive test result with no clinical signs of compression 
[14, 15]. This opinion is shared by Moore, who believes 
that the classic Adson’s maneuver is not applicable in 
current VTOS diagnosis [12]. 
For patients for whom the diagnosis of UEDVT is 
“highly probable,” we perform additional radiologic 
imaging examinations such as Doppler ultrasound, chest 
X-ray, computed tomography angiography or magnetic 
resonance angiography. These methods allow us to 
accurately determine the anatomic conditions as well 
as the hemodynamic significance of compression and 
the degree of venous obstruction [3]. 
An initial plain radiograph of the thoracic outlet — 
widely available, inexpensive and safe — is performed to 
rule out any underlying bone abnormalities that may be 
the cause of the analyzed compression symptoms and 
various forms of TOS — cervical ribs, bony anomalies 
of the first rib, clavicle, enlarged transverse processes 
of the last cervical vertebrae, or scarring after clavicle 
fracture. However, it should be remembered that this 
is only an initial imaging study. 
Ultrasonography is the first-line imaging modality 
in the diagnosis of UEDVT [10, 16]. It is performed 
after an initial clinical examination of the patient. 
For the diagnosis of DVT, its sensitivity is estimated 
at 78–100% and specificity at 82–100% [12]. More 
importantly, veins may be examined dynamically in var-
ious positions of the upper limb, which increases the 
imaging method’s diagnostic value [14, 16]. Changing 
the position of the limb makes it easier to determine 
whether the vein is compressed from the outside, and 
also visualize the location of stenosis within the vein. 
Duplex ultrasonography can also be used to assess 
blood flow. Significant flow acceleration indicates 
narrowing and compression, while an absence of flow 
suggests complete occlusion of the vessel. However, 
the accuracy of the examination depends on the ana-
tomical conditions of the patient and the examiner’s 
experience.
According to one group of researchers, duplex 
ultrasonography does not definitively exclude upper 
extremity deep vein thrombosis [17]. Bony structures 
are one obstacle in the assessment [16]. Another aspect 
that makes it difficult to assess subclavian vein thrombo-
sis is the development of good collateral circulation with 
rapid blood flow. In view of the above-mentioned limita-
tions, in order to definitively assess thrombotic changes 
in the veins of the upper extremity, contrast-enhanced 
imaging modalities are used. This is particularly impor-
tant in the assessment of chronic venous thrombosis 
lasting more than 6 weeks.
According to Vemuri, CT angiography is a valuable 
supplement to non-invasive ultrasonography in locating 
a compression of the proximal segment of the subcla-
vian vein. Additionally, axial scans provide information 
on the soft tissue structures (tumor, lymph nodes, 
thrombus, vessel wall) [1, 3].
Angio-MR is another recommended imaging mo-
dality in the assessment of venous compression syn-
dromes due to fibromuscular tissues. However, this 
examination requires more time in order to obtain 
the final result [3, 16].
Venography is the oldest and most invasive diagnos-
tic method since it involves a catheter being introduced 
into the vein and the injection of contrast. It is used 
when the diagnosis of compression is uncertain and for 
planned venous reconstructive surgery [1]. It remains 
the “golden standard” in the assessment of venous 
pathology and plays an important role intraoperatively 
in the assessment of blood flow through the subcla-
vian vein both prior to and following reconstructive 
or decompression surgery. It determines the extent 
and location of obstruction, the state of the collateral 
circulation, and the changes in blood flow in the vessel 
lumen [18]. 
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Complications of UEDVT include pulmonary embo-
lism (PE) and post-thrombotic syndrome (PTS). PE is di-
agnosed in 2–5% of patients with UEDVT, and according 
to some authors, even reaches up to 20% [1]. However, 
this type of complication is more often observed in sec-
ondary DVT [7, 8]. There are also authors who believe 
that the percentage of emboli originating in the deep 
veins of the upper limbs is unknown, because patients 
who do not present obvious symptoms of venous stasis 
are not examined for thrombosis [1, 19]. Therefore, 
an ultrasound examination of the veins of the upper 
limbs in search of the origin of pulmonary emboli should 
be performed each time the cause is unknown [1]. 
Apart from PE, other clinically relevant complications 
of DVT include: persistent or increased swelling of 
the limb after physical activity, bruising of the skin, 
heaviness of the affected limb, dilation of skin vessels 
or early recurrence of DVT. The above symptoms are 
referred to as late complications or post-thrombotic 
syndrome — PTS. It is estimated that it occurs in 7 to 
46% of cases of DVT. PTS is inseparably connected 
with the underlying cause of UEDVT and its ineffective 
treatment, which usually only involves anticoagulation 
therapy [1]. As is the case in May-Thurner syndrome, 
conservative treatment does not ensure complete res-
toration of patency [2, 20]. Therefore, after a period of 
improvement, the recurrence of DVT is observed, along 
with aggravated symptoms of impaired venous return, 
which leads to a proportion of patients with PTS and 
functional impairment of the affected limb.
The following elements should be considered in the 
management of UEDVT: rapid restoration of adequate 
blood flow with thromboprophylaxis, suppression of 
thrombus formation and inflammatory processes and 
restoration of limb function [21].
Secondary DVT, characterized by the presence of 
diagnostic catheters, pacemakers or malignancy in the 
vicinity of the vessel, is treated in accordance with the 
established guidelines based on randomized clinical 
trials and clinical practice. It is not recommended to 
remove all “foreign bodies”, especially when they are 
an important element in the treatment of the under-
lying disease. The mainstay of conservative treatment 
is anticoagulant therapy — low molecular weight hep-
arin (LMWH) in therapeutic doses for 5–7 days with 
the exception of hemodynamically unstable patients. 
Patients do not require laboratory monitoring beyond 
a periodic evaluation of platelet count. Monitoring 
anti-Xa activity is limited to cases of individual LMWH 
dosing in patients with renal insufficiency and extreme 
obesity. LMWH is used in conjunction with Vitamin K 
antagonists (VKA) until a stable INR value is achieved in 
the therapeutic range between 2–3. The acute phase of 
secondary DVT can also be treated with an intravenous 
infusion of unfractionated heparin UFH, monitoring 
its effectiveness by the elongation of the aPTT ratio 
by 1.5–2 times control in a repeat assay, 6 hours after 
its initiation. A new group of anticoagulants that has 
proven convenient and valuable in the treatment of 
DVT are direct thrombin inhibitors (factor IIa), such 
as Dabigatran, and direct factor Xa inhibitors (Rivar-
oxaban, Apixaban, Endoxaban). These Non-VKA Oral 
Anticoagulants (NOAC) selectively inhibit a specific 
coagulation factor [18]. When diagnosing primary, effort 
thrombosis in the course of VTOS in a young patient, 
in addition to restoring the patency of the subclavian 
vein, we strive to eliminate the root cause of thrombotic 
complications. We are treating a “healthy” patient who 
is professionally active and expects the full restoration 
of limb function. Based on the analysis of the available 
literature and the procedures adopted at an institution 
located in Poznan, it seems that the most appropriate 
course of action to achieve the above objective is the 
initial administration of LMWH with the concomitant 
introduction of a catheter into the subclavian vein and 
the performance of venography. Upon confirmation 
of thrombosis, local catheter-directed thrombolysis 
(CDT) is initiated. Two main types of thrombolytic 
drugs are currently in use: urokinase and rtPA. In the 
regimen adopted by the Department of Vascular and 
Intravascular Surgery, Angiology and Phlebology at 
Poznan University of Medical Sciences, rtPA is adminis-
tered directly to the thrombus at a rate of 1 mg/h with 
constant monitoring of fibrinogen, aPTT and platelet 
count. The maximum duration of treatment is 72 hours. 
Although in most cases acute (up to 14 days) DVT un-
dergoes local thrombolysis, in some patients residual 
thrombi may remain, which pose a risk of recurrence of 
thrombosis [10]. With the aim of restoring vein paten-
cy, sometimes more aggressive treatment is proposed 
in the form of a percutaneous pharmacomechanical 
thrombectomy (PMT) [12]. This method combines 
the local administration of a thrombolytic with the 
mechanical removal of the thrombus. Depending on 
the mechanism of thrombus removal, the following 
types of mechanical thrombectomy are distinguished: 
rotational (e.g. Aspirex), aspiration (e.g. Indigo system), 
rheolytic (e.g. AngioJet) and ultrasound-enhanced. The 
reduced thrombus burden after this type of treatment 
gives the opportunity to restore blood flow already 
after the first procedure [17]. Monitoring of the patient 
requires increased postoperative vigilance due to the 
risk of developing hemolytic complications. 
A review of the literature and data from various 
centers dealing selectively with VTOS shows that 
the mainstay of UEDVT treatment, in addition to the 
immediate restoration of blood flow, is the surgical de-
compression of the subclavian vein by first rib resection 
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along with the adjacent fibromuscular tissues [11, 20, 
22, 23]. The timing of the surgery and the extent of the 
procedure remains the topic of discussion. Advocates 
of urgent first rib resection explain their rationale with 
a concern for the recurrence of thrombosis [24]. Another 
option is performing the surgical decompression within 
4–6 weeks following fibrinolytic treatment [24–26]. 
In both cases, an extremely important component 
of further management and prognosis following the 
restoration of subclavian vein patency is its radiological 
assessment.
Algorithms for dealing with UEDVT have been intro-
duced [25, 26]. The assumption of the adopted VTOS 
treatment was the rapid restoration of the original ve-
nous blood flow (the “open vein” concept) and the sur-
gical removal of extravascular and intravascular changes 
within the subclavian vein. Although the final, long-term 
outcomes were improved, a percentage of patients still 
remained with a functional impairment of the limb. In 
2017, the work of Vazquez et al. was published, which 
analyzed 25 studies, in which the results of treatment 
of 1271 patients with UEDVT were discussed [13]. 
The resection of the first rib was obligatory for all 
patients. The primary criterion of assessment was 
the development of PTS, while the secondary crite-
rion was: DVT recurrence, PE, death, hemorrhage as 
well as re-operation with or without an endovascular 
procedure. In the final conclusions, the authors found 
that anticoagulant therapy alone does not protect the 
patient from the development of PTS and that surgical 
treatment with or without fibrinolysis is necessary to 
improve the final outcomes, which translates into an 
improved quality of life for the patients [1, 13]. There-
fore, modern surgical treatment of VTOS involves the 
complete decompression of the subclavian vein and en-
suring optimal blood flow. Vemuri et al. [1] recommend 
surgery after 4–6 weeks of effective thrombolysis. This 
prevents the recurrence of thrombosis and allows for 
the resolution of the adjacent inflammatory processes, 
while early (immediate) decompression is recommend-
ed in patients with severe obstruction. Moreover, they 
believe that the prophylactic decompression of inciden-
tally detected venous compression is unnecessary [12].
There are three main surgical approaches to sub-
clavian vein decompression. The first: transaxillary first 
rib resection with partial scalenectomy. This method 
was described and widely used by Machleder since 
1990 [11, 25, 26]. The procedure requires extensive 
knowledge of anatomy and surgical skills. The advantage 
of the method is a small, cosmetic postoperative scar 
and the creation of a wide space (following first rib re-
section) for the passing neurovascular structures. The 
disadvantage of this method is a small operative field and 
the inability to directly reconstruct the damaged vein. 
The next step in the procedure is an evaluation of the 
subclavian vein in venography after 2–3 weeks and in 
the case of persistent stenosis, balloon venoplasty with 
the continuation of oral anticoagulant therapy. The use 
of stents in the subclavian vein is not recommended, 
particularly in cases where first rib resection is not 
performed [23].
The infraclavicular approach described by Molina 
et al. [20] provides a good intraoperative view. It allows 
for wide exposure of the subclavian vein following the 
excision of the subclavius muscle, the costoclavicular 
ligament and the resection of the anterior part of the 
first rib. Such access facilitates the reconstruction of 
the vessel with the use of the patient’s great saphenous 
vein, insertion of a venous patch widening the vessel 
lumen or a biological patch. According to the authors of 
the method, the procedure should not be carried out 
more than two weeks after the onset of thrombotic 
symptoms or in patients with a long-segment occlusion 
or a venous diameter of less than 1 cm. The reconstruc-
tion surgery should be followed after 24 hours with 
a venogram [20]. Both methods give similar outcomes: 
75–80% of patients with VTOS remain without symp-
toms with a patent subclavian vein. Only in 20–25% of 
cases complications of thrombosis are observed, which 
are an indication for anticoagulant therapy [1].
The third group of proponents of aggressive decom-
pression of the subclavian vein in the thoracic outlet is 
composed of surgeons performing the resection from 
both the supraclavicular and infraclavicular approach. 
Good access to the regional anatomy obtained in this 
approach increases the extent and radicality of the re-
sected bone and fibromuscular structures compressing 
the vein. The aim of the surgery is the total resection of 
the first rib as well as the reconstruction of the scarred 
vein under visual inspection. Most often, these authors 
perform a reconstruction of the affected vein with an 
autologous venous patch or a bovine pericardial patch. 
In the case of vessel obstruction, the occluded fragment 
of the subclavian vein is replaced by a cryopreserved 
femoral vein [2, 5, 27]. In the case of a venous graft, a 
peripheral arteriovenous fistula is necessary [27]. The 
surgical procedure is supplemented by venography 
or intravascular ultrasound (IVUS), which provides 
objective information about the patency of the “de-
compressed” vein [2, 28]. Oral anticoagulant therapy 
is recommended for a minimum of three months, 
and 6–12 weeks after surgery patients can resume all 
normal activities. In addition to the advantages of ag-
gressive UEDVT treatment, the possible complications 
should be mentioned. The less serious complications 
include: pneumothorax, hematoma, lymphedema or 
post-operative wound infection. In view of the infre-
quency of the performed operations the following 
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severe complications are described in the literature: 
permanent damage to the brachial plexus, damage to 
the long thoracic nerve, diaphragmatic nerve or finally 
recurrent thrombosis of the reconstructed subclavian 
vein [1]. The possibility of developing late complications 
of UEDVT, the need for precise diagnostic imaging, and 
the identification of an effective treatment method all 
point to the need to create centers specializing in the 
treatment of upper limb thrombosis.
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